Potential use of glutathione as a treatment for Parkinson's disease
- Hai-Li Wang
- Jun Zhang
- Yu-Ping Li
- Lun Dong
- Ying-Zhu Chen
Affiliations: Department of Clinical Medicine, Dalian Medical University, Dalian, Liaoning 116000, P.R. China, Department of Neurosurgery, Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu 225001, P.R. China, Department of Neurology, Clinical Medical College of Yangzhou University, Yangzhou, Jiangsu 225001, P.R. China
- Published online on: December 4, 2020 https://doi.org/10.3892/etm.2020.9557
Copyright: © Wang
et al. This is an open access article distributed under the
terms of Creative
Commons Attribution License.
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
The aim of the present study was to assess the efficacy and safety of glutathione (GSH) for the treatment of Parkinson's disease (PD). The PubMed, Cochrane Library, OvidSP, Web of Science, China Science and Technology Journal Database, Chinese National Knowledge Infrastructure and China Wanfang Standards Database databases were systematically searched from the inception dates to October 1st, 2019, using the key words‘glutathione’ or ‘GSH’ and ‘Parkinson’ or ‘Parkinson's disease’ or ‘PD’. The quality of the included articles was assessed using the bias risk assessment tool of the Cochrane systematic evaluator manual (version 5.1.0). Pooled analysis of the relevant data was performed using RevMan 5.3 software and subgroup analysis was performed to determine the impact of the dosage (300 vs. 600 mg) on the outcome measures. A total of seven randomized controlled trials involving 450 participants were included in the meta‑analysis. The results of the present study indicated a statistically significant difference between the GSH and control groups, in terms of the Unified Parkinson's Disease Rating Scale (UPDRS) III [standard mean difference (SMD), ‑0.48; 95% CI, ‑(0.88‑0.08); P=0.02] and GSH peroxidase (SMD, 1.88; 95% CI, 0.52‑3.24; P=0.007). However, the differences in the UPDRS I (SMD, ‑0.04; 95% CI, ‑0.25‑0.16; P=0.70) and UPDRS II (SMD, 0.03; 95% CI, ‑0.17‑0.24; P=0.77) score and in side effects were not statistically significant between the groups. Subgroup analyses revealed that the dosage (300 vs. 600 mg) was an influencing factor for UPDRS III. The present study demonstrated that GSH may mildly improve motor scores in PD, but not at the expense of increased adverse events.